retatrutide studie Triple Agonist (GLP-1/GIP/GCG) Demand for Unapproved Weight-Loss Drug
Description
, Liu, Y
The SmPC recommends monitoring thyroid function when these medications are co-prescribed
Through Fella, semaglutide users lose an average of 16.9% of their body weight
However, both medications affect the gastrointestinal systemtirzepatide by slowing motility and orlistat by preventing fat absorptionwhich may compound digestive side effects when used together
Canagliflozin EMA product information (2023)
